| Oncogenic mutants of RON and MET receptor tyrosine kinases cause activation of the beta-catenin pathway. | None |
| Wnt-1 and int-2 mammary oncogene effects on the beta-catenin pathway in immortalized mouse mammary epithelial cells are not sufficient for tumorigenesis. | None |
| Oncogenic beta-catenin is required for bone morphogenetic protein 4 expression in human cancer cells. | None |
| Oncogenic transformation by beta-catenin: deletion analysis and characterization of selected target genes. | None |
| Proof-of-principle: oncogenic beta-catenin is a valid molecular target for the development of pharmacological inhibitors. | None |
| Protein evolution: structure-function relationships of the oncogene beta-catenin in the evolution of multicellular animals. | None |
| Small-molecule antagonists of the oncogenic Tcf/beta-catenin protein complex. | None |
| Phosphorylation and ubiquitination of oncogenic mutants of beta-catenin containing substitutions at Asp32. | None |
| Solution structure of a peptide derived from the oncogenic protein beta-Catenin in its phosphorylated and nonphosphorylated states. | None |
| STD and TRNOESY NMR studies on the conformation of the oncogenic protein beta-catenin containing the phosphorylated motif DpSGXXpS bound to the beta-TrCP protein. | None |
| analysis of conformation of the oncogenic protein beta-catenin containing the phosphorylated motif DpSGXXpS bound to the beta-TrCP protein | None |
| Synergistic activation of the murine gastrin promoter by oncogenic Ras and beta-catenin involves SMAD recruitment. | None |
| found a strong (25- to 40-fold) synergistic stimulation of the gastrin promoter by the combination of oncogenic beta-catenin and K-ras overexpression | None |
| Beta-catenin interacts with the FUS proto-oncogene product and regulates pre-mRNA splicing. | None |
| Construction of a novel DNA decoy that inhibits the oncogenic beta-catenin/T-cell factor pathway. | None |
| STD and TRNOESY NMR studies for the epitope mapping of the phosphorylation motif of the oncogenic protein beta-catenin recognized by a selective monoclonal antibody. | None |
| Modulation of the oncogenic potential of beta-catenin by the subcellular distribution of plakoglobin. | None |
| Catnb expression results in p53-independent DNA damage and oncogene-induced senescence in prelymphamogenic thymocytes in vivo. | None |
| PTPRK negatively regulates transcriptional activity of wild type and mutated oncogenic beta-catenin and affects membrane distribution of beta-catenin/E-cadherin complexes in cancer cells. | None |
| An oncogenic hub: beta-catenin as a molecular target for cancer therapeutics. | None |